Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Malaria: early-phase trial registry
6 of 28 indexed Malaria trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #577 of 28,707 conditions by registered trial count.
28 US clinical trials · 6 currently recruiting · #577 of 28,707 conditions by registered trial count
Malaria: 28 US clinical trials tracked, 6 recruiting.
Malaria is the subject of 28 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 14 of these trials.
Enrollment posture brief
Registry condition malaria
OPEN 6 | RECR 21% | LATE 0 | EARLY 21 | RANK #577 | SPON 14
Volume-matched condition peers
Nearest open-share peer: Cervical Adenocarcinoma (21% recruiting · 14 trials)
Malaria lists 6 open slots (21% of 28 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Malaria on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Malaria is recruiting below its size-band peers.
6 of 28 indexed trials (21.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Malaria research.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 14 of 28 trials (50%). 9 distinct sponsors appear on at least one study for this condition label.
-
Most Malaria trials plan to enrol fewer than 100 people.
Median target enrolment is 71 among the 28 trials that report a genuine target (sentinel values excluded). 17 of those (60.7%) plan for fewer than 100 participants.
-
Malaria research is mostly interventional.
23 interventional and 5 observational studies make up this index (82.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
28 total, page 1 of 1
Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge
National Institute of Allergy and Infectious Diseases (NIAID)
NCT02639299
Evaluation, Treatment and Monitoring of Patients With a Known or Suspected Parasitic Infection
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001645
Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays
National Institute of Allergy and Infectious Diseases (NIAID)
NCT06607003
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
National Institute of Allergy and Infectious Diseases (NIAID)
NCT03937817
A Study of Oral E1018 in Healthy Adult Participants
Eisai
NCT06854042
Observational Study of the Safety of Intravenous Artesunate Treatment of Pregnant Women and Their Infants
Amivas
NCT05285735
A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria
BioNTech SE
NCT06069544
First-in-Human PfSPZ-LARC2 Vaccination/CHMI
National Institute of Allergy and Infectious Diseases (NIAID)
NCT06735209
Malaria Clinical Trials Center General Screening
Fred Hutchinson Cancer Center
NCT02119312
Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and Mali
National Institute of Allergy and Infectious Diseases (NIAID)
NCT02334462
Phase I Study of the Safety and Immunogenicity of BSAM-2/Alhydrogel +CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria in Adults in the US and Mali
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00889616
Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults
GlaxoSmithKline
NCT03162614
Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT02015091
Safety and Efficacy Study of RTS,S AS02A/AS01B Vaccine to Prevent Malaria
U.S. Army Medical Research and Development Command
NCT00075049
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
National Institute of Allergy and Infectious Diseases (NIAID)
NCT03641339
Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria
U.S. Army Medical Research and Development Command
NCT00870987
Trial to Evaluate CIS43LS in Healthy Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04206332
Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults
GlaxoSmithKline
NCT01366534
Experimental PfSPZ Vaccine in Adults Without Malaria
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01441167
Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults
Gates Medical Research Institute
NCT05891236
Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults
U.S. Army Medical Research and Development Command
NCT01540474
Weekly Dosing of Malarone ® for Prevention of Malaria
U.S. Army Medical Research and Development Command
NCT00984256
Merozoite Surface Protein 1 Antibody Response in Asymptomatic Human Malaria Infection
U.S. Army Medical Research and Development Command
NCT00761020
Sanaria™ PfSPZ Challenge Vaccine
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01546389
Initial Study of Malaria Vaccine Pfs25-EPA/Alhydrogel(Registered Trademark)
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01434381
Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America
U.S. Army Medical Research and Development Command
NCT00312702
Food-Effect Bioavailability Study of AQ-13, a Candidate Antimalarial
Tulane University Health Sciences Center
NCT00455494
Blood-Stage Plasmodium Vivax Cell Bank
National Institute of Allergy and Infectious Diseases (NIAID)
NCT05095272
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 18 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Malaria records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Malaria trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Malaria page
28 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Malaria trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most Malaria trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Malaria condition card totals 28 registered trials; most-linked intervention PfSPZ Vaccine; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.